EGFR and neoplasm: For instance, UDCA not only can inhibit the activation of the EGFR-ERK pathway, thereby suppressing the proliferation of cholangiocarcinoma cells, but also can inhibit the expression of PI3K and AKT, providing further evidence for its anti-tumor effects in cholangiocarcinoma cells (Lee et al. 2021).